| Nonprogressive | Chronic | p-value | |
| Subjects | 45 | 46 | |
| Age years | 49.2±10.2 | 52.8±10.6 | 0.11 |
| Range | (33–74) | (30–76) | |
| Females | 26 (58) | 31 (67) | 0.39 |
| Time from diagnosis to enrolment years | 2.87±3.9 | 8.01±9.06 | <0.01 |
| Race | |||
| African-American | 5 | 7 | 0.76 |
| White | 35 | 31 | 0.35 |
| Other | 5 | 8 | 0.55 |
| Ethnicity | |||
| Latino | 2 | 5 | 0.43 |
| Scadding stage 0/I/II/III/IV | 4/6/20/6/9 | 5/2/22/5/12 | 0.64 |
| Lymphocyte count ×109 cells·L−1 | 1.24±0.5 | 1.32±1.1 | 0.64 |
| Systemic immunosuppression at enrolment | 14 (31) | 30 (65) | <0.01 |
| Pulmonary function testing % predicted | |||
| FVC | 102.4±12.5 | 91.2±16.7 | <0.01 |
| FEV1 | 97.8±16.8 | 86.7±18.8 | <0.01 |
| DLCO | 89.8±18.1# | 73.4±20.2¶ | <0.01 |
Data are presented as n, mean±sd or n (%), unless otherwise stated. FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide. #: n=31; ¶: n=26.